Skip to content
MatchScript
Menu

Head-to-head · The Match Score

Enhance MD vs CoreAge Rx

Both scored on the same six-factor Match Score. CoreAge Rx wins this matchup with a 91 to 85 edge.

Enhance MD

#6 · Grade B

Patients who value clear tiered pricing and ongoing lab-backed provider care more than the lowest sticker price — and don't need brand or a pill.

Visit Enhance MD
VS
Higher Match Score

CoreAge Rx

#1 · Grade A−

Anyone who wants transparent flat pricing, fast nationwide access, and no teaser-rate bait-and-switch.

Visit CoreAge Rx

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
80
82
Speed to Start
80
97
Formulary Match
84
80
Support Level
90
93
Flexibility
84
97
Transparency
92
95

Price, coverage & formulary

DetailEnhance MDCoreAge Rx
Semaglutide$212/mo$149/mo
Tirzepatide$280/mo$349/mo
Coverage39 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjectable onlyInjectable only
Match Score85 · B91 · A−
Winner: CoreAge Rx

CoreAge Rx is our #1-ranked provider overall, and it takes this matchup too — a 91 Match Score to Enhance MD's 85. The best all-around match: nationwide access, both molecules at one flat, no-surprise price, and an easy exit.

Enhance MD is still a fair pick if its strengths line up with yours — best for: Patients who value clear tiered pricing and ongoing lab-backed provider care more than the lowest sticker price — and don't need brand or a pill.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full Enhance MD reviewFull CoreAge Rx review

More head-to-heads

Or browse alternatives to CoreAge Rx and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.